Iovance Biotherapeutics Inc. held its Annual Meeting of Stockholders on June 10, 2025, via live webcast. Stockholders voted on several proposals: the election of Iain Dukes, Athena Countouriotis, Ryan Maynard, Wayne Rothbaum, Frederick Vogt, Michael Weiser, and Wendy Yarno to the Board of Directors was approved. The ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved. An amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant by 12,500,000 shares was approved. An amendment to the 2020 Employee Stock Purchase Plan to increase the number of shares available for grant by 1,000,000 shares was approved.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。